Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GMT.WAR
- Price
- 4.98
- Stock movement up
- +0.18 (3.75%)
- Company name
- Genomtec S.A.
- Exchange
- (WAR ,
- Currency
- PLN )
- Sector
- Healthcare >Medical Devices
- Market cap
- 75.02M
- Ent value
- 69.91M
- Price/Sales
- 12503.65
- Price/Book
- 4.95
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-11-19
DIVIDENDS
GMT.WAR does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 12503.65 |
| Price to Book | 4.95 |
| EV to Sales | 11652.15 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 15.06M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 13.84M |
| Net receivables | 1.09M |
| Total current assets | 15.87M |
| Goodwill | 0.00 |
| Intangible assets | 5.51M |
| Property, plant and equipment | 5.70M |
| Total assets | 23.90M |
| Accounts payable | 533.00K |
| Short/Current long term debt | 2.58M |
| Total current liabilities | 5.15M |
| Total liabilities | 8.73M |
| Shareholder's equity | 15.17M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.80 |
| Daily high | 5.00 |
| Daily low | 4.73 |
| Daily Volume | 7K |
| All-time high | 7.07 |
| 1y analyst estimate | - |
| Beta | 0.14 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| GMT.WAR | S&P500 | |
| Current price drop from All-time high | -29.56% | -3.60% |
| Highest price drop | -34.23% | -19.00% |
| Date of highest drop | 10 Nov 2025 | 8 Apr 2025 |
| Avg drop from high | -15.61% | -2.72% |
| Avg time to new high | 13 days | 5 days |
| Max time to new high | 38 days | 89 days |
COMPANY DETAILS
Marketcap
75.02M
Marketcap category
Small-cap
Description
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, the company develops and commercializes tests used in the detection of viral infectious diseases and other areas. Genomtec S.A. was incorporated in 2008 and is based in Wroclaw, Poland.
Employees
26
Website
Investor relations
-
SEC filings
CEO
Country
Poland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found